Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Hepatitis C

Free Subscription 23.01.2012 1 BMC Gastroenterol 2 Gastroenterology 1 Hepatogastroenterology 1 J Gastroenterol 1 J Hepatol 2 J Med Virol 26 J Viral Hepat 2 N Engl J Med

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

BMC Gastroenterol

1. LIN KH , Hsu PI, Yu HC, Lin CK, et al
   Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis c and pretreatment low platelet counts.
   BMC Gastroenterol. 2012;12:7.
   PubMed     Text format     Related articles    Abstract available
   
   
   

   
   Gastroenterology

2. THOMAS E , Gonzalez VD, Li Q, Modi AA, et al
   HCV Infection Induces a Unique Hepatic Innate Immune Response Associated with Robust Production of Type III Interferons.
   Gastroenterology. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
3. CHU TW , Kulkarni R, Gane EJ, Roberts SK, et al
   Effect of IL28B Genotype on Early Viral Kinetics during Interferon-Free Treatment of Patients with Chronic Hepatitis C.
   Gastroenterology. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   

   
   Hepatogastroenterology

4. CHOI Y , Jeon WK, Hwang SJ, Kim BI, et al
   The role of the gut barrier function in the pathophysiology of viral liver cirrhosis.
   Hepatogastroenterology. 2011;58:1244-7.
   PubMed     Text format     Related articles    Abstract available
   
   
   

   
   J Gastroenterol

5. MURAKAMI K , Takahashi R, Ono M, Watanabe K, et al
   Serodiagnosis of Helicobacter hepaticus infection in patients with liver and gastrointestinal diseases: western blot analysis and ELISA using a highly specific monoclonal antibody for H. hepaticus antigen.
   J Gastroenterol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   

   
   J Hepatol

6. GUEDJ J , Dahari H, Pohl RT, Ferenci P, et al
   Understanding silibinin's modes of action against HCV using viral kinetic modeling.
   J Hepatol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   

   
   J Med Virol

7. HAYASHI K , Katano Y, Kuzuya T, Tachi Y, et al
   Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.
   J Med Virol. 2012;84:438-44.
   PubMed     Text format     Related articles    Abstract available
   
   
   
8. CHARY A , Winters MA, Eisen R, Knight TH, et al
   Quantitation of hepatitis C virus RNA in peripheral blood mononuclear cells in HCV-monoinfection and HIV/HCV-coinfection.
   J Med Virol. 2012;84:431-7.
   PubMed     Text format     Related articles    Abstract available
   
   
   

   
   J Viral Hepat

9. KRONENBERGER B , Zeuzem S
   New developments in HCV therapy.
   J Viral Hepat. 2012;19 Suppl 1:48-51.
   PubMed     Text format     Related articles    Abstract available
   
   
   
10. NEGRO F
    Steatosis and insulin resistance in response to treatment of chronic hepatitis C.
    J Viral Hepat. 2012;19 Suppl 1:42-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
11. RUMI M , Aghemo A, Prati GM
    Comparative trials of peginterferon alpha2a and peginterferon alpha2b for chronic hepatitis C.
    J Viral Hepat. 2012;19 Suppl 1:37-41.
    PubMed     Text format     Related articles    Abstract available
    
    
    
12. SEBASTIANI G , Alberti A
    How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C?
    J Viral Hepat. 2012;19 Suppl 1:18-32.
    PubMed     Text format     Related articles    Abstract available
    
    
    
13. SIMON-TALERO M , Buti M, Esteban R
    Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction?
    J Viral Hepat. 2012;19 Suppl 1:14-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
14. FERENCI P
    Optimal treatment duration for patients with HCV genotype 1 infection.
    J Viral Hepat. 2012;19 Suppl 1:7-13.
    PubMed     Text format     Related articles    Abstract available
    
    
    
15. DEGASPERI E , Aghemo A
    Clinical drivers in naive patient eligibility for treatment of chronic hepatitis C.
    J Viral Hepat. 2012;19 Suppl 1:3-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
16. MARUOKA D , Imazeki F, Arai M, Kanda T, et al
    Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long-term follow-up.
    J Viral Hepat. 2012;19:e97-e104.
    PubMed     Text format     Related articles    Abstract available
    
    
    
17. GROVER VP , Pavese N, Koh SB, Wylezinska M, et al
    Cerebral microglial activation in patients with hepatitis c: in vivo evidence of neuroinflammation.
    J Viral Hepat. 2012;19:e89-e96.
    PubMed     Text format     Related articles    Abstract available
    
    
    
18. BACHMETOV L , Gal-Tanamy M, Shapira A, Vorobeychik M, et al
    Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity.
    J Viral Hepat. 2012;19:e81-e88.
    PubMed     Text format     Related articles    Abstract available
    
    
    
19. RANCE E , Tanner JE, Alfieri C
    Inhibition of IkappaB kinase by thalidomide increases hepatitis C virus RNA replication.
    J Viral Hepat. 2012;19:e73-80.
    PubMed     Text format     Related articles    Abstract available
    
    
    
20. KAWAGUCHI T , Ide T, Itou M, Suetsugu M, et al
    Ischaemic colitis during interferon treatment for chronic hepatitis C: report of two cases and literature review.
    J Viral Hepat. 2012;19:e220-4.
    PubMed     Text format     Related articles    Abstract available
    
    
    
21. ALMARIO CV , Vega M, Trooskin SB, Navarro VJ, et al
    Examining hepatitis c virus testing practices in primary care clinics.
    J Viral Hepat. 2012;19:e163-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
22. CHENG JC , Yeh YJ, Huang YH, Liang KH, et al
    Hepatic expression of MxA and OAS1 in an ex vivo liver slice assay independently predicts treatment outcomes in chronic hepatitis C.
    J Viral Hepat. 2012;19:e154-62.
    PubMed     Text format     Related articles    Abstract available
    
    
    
23. CALES P , Zarski JP, Marc Chapplain J, Bertrais S, et al
    Fibrosis progression under maintenance interferon in hepatitis C is better detected by blood test than liver morphometry.
    J Viral Hepat. 2012;19:e143-e153.
    PubMed     Text format     Related articles    Abstract available
    
    
    
24. HAYASHI N , Okanoue T, Tsubouchi H, Toyota J, et al
    Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C.
    J Viral Hepat. 2012;19:e134-e142.
    PubMed     Text format     Related articles    Abstract available
    
    
    
25. MIKI D , Ohishi W, Ochi H, Hayes CN, et al
    Serum PAI-1 is a novel predictor for response to pegylated interferon-alpha-2b plus ribavirin therapy in chronic hepatitis C virus infection.
    J Viral Hepat. 2012;19:e126-e133.
    PubMed     Text format     Related articles    Abstract available
    
    
    
26. CRAXI A , Koutsounas S, Ogurtsov P, Chemello L, et al
    Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response.
    J Viral Hepat. 2012;19:e120-e125.
    PubMed     Text format     Related articles    Abstract available
    
    
    
27. YAMADA I , Suzuki F, Kamiya N, Aoki K, et al
    Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection.
    J Viral Hepat. 2012;19:e112-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
28. HO EY , Ha NB, Ahmed A, Ayoub W, et al
    Prospective study of risk factors for hepatitis C virus acquisition by Caucasian, Hispanic, and Asian American patients.
    J Viral Hepat. 2012;19:e105-11.
    PubMed     Text format     Related articles    Abstract available
    
    
    
29. KATSOUNAS A , Trippler M, Wang B, Polis M, et al
    CCL5 mRNA is a marker for early fibrosis in chronic hepatitis C and is regulated by interferon-alpha therapy and toll-like receptor 3 signalling.
    J Viral Hepat. 2012;19:128-37.
    PubMed     Text format     Related articles    Abstract available
    
    
    
30. VERMEHREN J , Susser S, Lange CM, Forestier N, et al
    Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b.
    J Viral Hepat. 2012;19:120-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
31. JAFFERBHOY H , Miller MH, Dunbar JK, Tait J, et al
    Intravenous drug use: not a barrier to achieving a sustained virological response in HCV infection.
    J Viral Hepat. 2012;19:112-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
32. REAU N , Hamzeh FM, Lentz E, Zhou X, et al
    Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin.
    J Viral Hepat. 2012;19:94-102.
    PubMed     Text format     Related articles    Abstract available
    
    
    
33. ALAVIAN SM , Tabatabaei SV, Behnava B
    Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis.
    J Viral Hepat. 2012;19:88-93.
    PubMed     Text format     Related articles    Abstract available
    
    
    
34. STICKEL F , Helbling B, Heim M, Geier A, et al
    Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C.
    J Viral Hepat. 2012;19:77-87.
    PubMed     Text format     Related articles    Abstract available
    
    
    

    
    N Engl J Med

35. CHUNG RT
    A watershed moment in the treatment of hepatitis C.
    N Engl J Med. 2012;366:273-5.
    PubMed     Text format     Related articles   
    
    
    
36. LOK AS , Gardiner DF, Lawitz E, Martorell C, et al
    Preliminary study of two antiviral agents for hepatitis C genotype 1.
    N Engl J Med. 2012;366:216-24.
    PubMed     Text format     Related articles    Abstract available
    
    
    

Thank you for your interest in scientific medicine.

This service is provided by AMEDEO through an unrestricted educational grant from F. Hoffmann-La Roche.

Amedeo is a Flying Publisher website.    Design: